
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing allantoin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing allantoin is listed. Products containing it are filed in the directory as over-the-counter monograph drugs and unapproved drugs, in gel, cream, ointment, tablet and liquid forms.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Allantoin is a skin protectant found in over-the-counter skin products that a pharmacy may also compound into topical creams when a prescriber orders it.
Allantoin is a small nitrogen-containing compound (an imidazolidine-2,4-dione) that occurs naturally as a human metabolite; ChEBI classes it as a vulnerary, meaning a wound-healing agent. It is one of the active ingredients listed in the FDA's over-the-counter (OTC) skin protectant monograph (21 CFR part 347, monograph M016). Skin protectants temporarily protect injured or exposed skin from harmful or annoying stimuli. Products such as Coats Aloe cream, marketed under that OTC monograph, are labeled to temporarily protect minor cuts, scrapes and burns, and to help prevent and protect chafed, chapped or cracked skin and skin exposed to wind and cold. A search of Drugs@FDA found no prescription allantoin product. A prescriber might order allantoin compounded in a cream base, strength or form that is not sold over the counter. Compounded preparations are not FDA-approved and require a prescription.
Allantoin OTC labels carry no boxed warning. Allantoin is for use on the skin only: keep it out of the eyes, and do not use it on deep or puncture wounds, animal bites or serious burns. Stop use and ask a doctor if the condition worsens, if symptoms last more than 7 days, or if they clear up and come back within a few days. If it is swallowed, get medical help or contact a poison control center right away. The cited label lists no drug interactions. The OTC label gives no pregnancy or breastfeeding statement and no LactMed record for allantoin was found, so ask before using it if you are pregnant or breastfeeding. A compounded preparation may contain other ingredients that carry their own warnings. If you notice a skin reaction or any other side effect, talk to your prescriber or pharmacist.
Allantoin is described by ChEBI as an imidazolidine-2,4-dione and a human metabolite with a vulnerary role. Mechanistic data are limited: in a rat open-wound model, an oil-in-water lotion containing allantoin was associated with regulation of the inflammatory response and stimulation of fibroblast proliferation and extracellular matrix synthesis (Araújo et al., Acta Cir Bras 2010); that study did not involve humans. Systemic pharmacokinetic data for topical allantoin were not found in the sources reviewed. Regulatory status: allantoin is a listed skin protectant active ingredient in 21 CFR 347.10 (OTC monograph M016), with labeling in 21 CFR 347.50 limited to temporary protection of minor cuts, scrapes and burns and of chafed, chapped or cracked skin, including protection from wind and cold. An openFDA Drugs@FDA query returned no NDA or ANDA for allantoin. Prescribers have ordered compounded allantoin in topical creams; IJPC has published a coal tar and allantoin cream formulation (Allen, 2007). Uses outside the monograph statements fall outside 21 CFR part 347; OTC monograph products are not individually FDA-approved. Dosing is per prescriber. Monitor the treated area for worsening or for symptoms lasting more than 7 days, per the monograph warnings, and for reactions to other ingredients in the base.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)